Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma: Relationship With Prognostic Factors and Response to Neoadjuvant Chemotherapy
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Poor prognostic factors in patients with TNBC
研究概览
简要总结
Triple-negative breast carcinoma is characterized by the absence of estrogen receptors, progesterone receptors, and HER2/neu receptors. Carbonic anhydrase IX (CA IX) is a tumor-associated cell surface glycoprotein that is involved in adaptation to hypoxia-induced acidosis and plays a role in cancer progression. This study aimed to investigate CA IX expression in TNBC and its relationship with treatment effect.
详细描述
Tru-cut biopsy materials, sent to our hospital pathology laboratory between August 2018 and May 2023, will be examined. Invasive carcinoma cases will be evaluated according to estrogen, progesterone, and HER 2 receptor levels. Triple-negative tumor cases were isolated and those cases who underwent breast resection in our hospital after receiving neoadjuvant chemotherapy (Adriamycin, cyclophosphamide, and then paclitaxel for 4 cycles) were included in the study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Older than 18 years
- •Triple-negative mastectomy cases
- •Patients whose data can be available
- •Patients who were operated in our hospital
排除标准
- •Younger than 18 years
- •Not triple negative mastectomy cases
- •Patients with missing data
- •Patients who were operated in another hospital
结局指标
主要结局
Poor prognostic factors in patients with TNBC
时间窗: 2018-2023
Higher staining CA IX levels (≥ 10%) in TNBC patients' pathological specimens is a poor prognostic factor
The treatment success with inhibiting the CA IX enzyme levels' effectiveness
时间窗: 2018-2023
Treatment success in TNBC patients by evaluating changes in CA IX staining levels
次要结局
未报告次要终点
研究者
Mehmet Buğra Bozan
Professor, Associate
Elazıg Fethi Sekin Sehir Hastanesi